30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Centinel Spine Announces prodisc C Clinical Trials -

Centinel Spine received Investigational Device Exemption approval to initiate a two-level clinical trial with prodisc® C Vivo and prodisc C SK anterior cervical total disc replacement devices (TDRs). The two-level prospective, randomized study will evaluate the devices at multiple sites throughout the U.S., comparing them to an existing TDR currently approved by FDA for two-level indications to validate their safety and effectiveness. prodisc C Vivo has been used ex-U.S. since 2009. prodisc C SK is a variation of prodisc C Nova, an implant used ex-U.S. since 2010. prodisc C Vivo and prodisc C SK employ the same mechanism of action as the currently-marketed prodiscC implant that was granted premarket approval in 2007. Their principal difference lies in the way in which the devices interface with the vertebral body; the variations are intended to allow a better match of the implant to a patient's anatomy. (Centinel Spine, 7/19/19)